Ocugen to License Modifier Gene Therapy for Retinitis Pigmentosa in Korea

 

• Upfront fees and near-term development milestone payments totaling up to $11 million
• Sales milestones of $150 million or more in first 10 years of commercialization
• Royalties equaling 25% of net sales
• Ocugen to manufacture and supply OCU400

https://finviz.com/news/74039/ocugen-inc-announces-signing-of-binding-term-sheet-for-the-license-of-ocu400-modifier-gene-therapy-for-retinitis-pigmentosa-in-korea